309 related articles for article (PubMed ID: 25874884)
21. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
[TBL] [Abstract][Full Text] [Related]
22. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
23. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer.
Baloria U; Akhoon BA; Gupta SK; Sharma S; Verma V
Amino Acids; 2012 Apr; 42(4):1349-60. PubMed ID: 21229277
[TBL] [Abstract][Full Text] [Related]
24. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
25. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of Brain Cancer.
Roth P; Preusser M; Weller M
Oncol Res Treat; 2016; 39(6):326-34. PubMed ID: 27260656
[TBL] [Abstract][Full Text] [Related]
27. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.
Arens R; van Hall T; van der Burg SH; Ossendorp F; Melief CJ
Semin Immunol; 2013 Apr; 25(2):182-90. PubMed ID: 23706598
[TBL] [Abstract][Full Text] [Related]
28. Mimotope vaccines for cancer immunotherapy.
Sharav T; Wiesmüller KH; Walden P
Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
[TBL] [Abstract][Full Text] [Related]
29. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.
Foy KC; Miller MJ; Moldovan N; Carson WE; Kaumaya PT
Oncoimmunology; 2012 Oct; 1(7):1048-1060. PubMed ID: 23170253
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
31. [Vaccination strategies for solid tumors--fundamentals, limitations, and recent results].
Atanackovic D
Ther Umsch; 2004 Jun; 61(6):389-96. PubMed ID: 15253165
[TBL] [Abstract][Full Text] [Related]
32. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
33. In silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor.
Bayrami V; Keyhanfar M; Mohabatkar H; Mahdavi M; Moreau V
Mol Biol Res Commun; 2016 Dec; 5(4):201-214. PubMed ID: 28261624
[TBL] [Abstract][Full Text] [Related]
34. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
35. Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.
Shi J; Zhang J; Li S; Sun J; Teng Y; Wu M; Li J; Li Y; Hu N; Wang H; Hu Y
PLoS One; 2015; 10(12):e0144475. PubMed ID: 26641892
[TBL] [Abstract][Full Text] [Related]
36. Designing B-Cell Epitopes for Immunotherapy and Subunit Vaccines.
Singh H; Gupta S; Gautam A; Raghava GP
Methods Mol Biol; 2015; 1348():327-40. PubMed ID: 26424284
[TBL] [Abstract][Full Text] [Related]
37. Predicted B-cell epitopes of HER-2 oncoprotein by a bioinformatics method: a clue for breast cancer vaccine development.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(1):137-8. PubMed ID: 17477789
[TBL] [Abstract][Full Text] [Related]
38. Perspectives for immunotherapy in glioblastoma treatment.
Finocchiaro G; Pellegatta S
Curr Opin Oncol; 2014 Nov; 26(6):608-14. PubMed ID: 25210870
[TBL] [Abstract][Full Text] [Related]
39. Immunoinformatics and modeling perspective of T cell epitope-based cancer immunotherapy: a holistic picture.
Mishra S; Sinha S
J Biomol Struct Dyn; 2009 Dec; 27(3):293-306. PubMed ID: 19795913
[TBL] [Abstract][Full Text] [Related]
40. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
